Bone disease in multiple myeloma

Homare Eda, Loredana Santo, G. David Roodman, Noopur Raje

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90 % of patients with MM develop osteolytic bone lesions, frequently complicated by skeletal-related events (SRE) such as severe bone pain, pathological fractures, vertebral collapse, hypercalcemia, and spinal cord compression. All of these not only result in a negative impact on quality of life but also adversely impact overall survival. OBD is a consequence of increased osteoclast (OC) activation along with osteoblast (OB) inhibition, resulting in altered bone remodeling. OC number and activity are increased in MM via cytokine deregulation within the bone marrow (BM) milieu, whereas negative regulators of OB differentiation suppress bone formation. Inhibition of osteolysis and stimulation of OB differentiation leads to reduced tumor growth in vivo. Therefore, novel agents targeting OBD are promising therapeutic strategies not only for the treatment of MM OBD but also for the treatment of MM. Several novel agents in addition to bisphosphonates are currently under investigation for their positive effect on bone remodeling via OC inhibition or OB stimulation. Future studies will look to combine or sequence all of these agents with the goal of not only alleviating morbidity from MM OBD but also capitalizing on the resultant antitumor activity.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages251-270
Number of pages20
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Publication series

NameCancer Treatment and Research
Volume169
ISSN (Print)0927-3042

Fingerprint

Bone Diseases
Multiple Myeloma
Osteoblasts
Osteoclasts
Bone Remodeling
Bone and Bones
Spontaneous Fractures
Spinal Cord Compression
Osteolysis
Metabolic Bone Diseases
Diphosphonates
Hypercalcemia
Osteogenesis
Therapeutics
Bone Marrow
Quality of Life
Cytokines
Morbidity
Pain
Survival

Keywords

  • Bone disease
  • Multiple myeloma
  • Therapies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Eda, H., Santo, L., Roodman, G. D., & Raje, N. (2016). Bone disease in multiple myeloma. In Cancer Treatment and Research (pp. 251-270). (Cancer Treatment and Research; Vol. 169). Kluwer Academic Publishers. https://doi.org/10.1007/978-3-319-40320-5_14

Bone disease in multiple myeloma. / Eda, Homare; Santo, Loredana; Roodman, G. David; Raje, Noopur.

Cancer Treatment and Research. Kluwer Academic Publishers, 2016. p. 251-270 (Cancer Treatment and Research; Vol. 169).

Research output: Chapter in Book/Report/Conference proceedingChapter

Eda, H, Santo, L, Roodman, GD & Raje, N 2016, Bone disease in multiple myeloma. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 169, Kluwer Academic Publishers, pp. 251-270. https://doi.org/10.1007/978-3-319-40320-5_14
Eda H, Santo L, Roodman GD, Raje N. Bone disease in multiple myeloma. In Cancer Treatment and Research. Kluwer Academic Publishers. 2016. p. 251-270. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-40320-5_14
Eda, Homare ; Santo, Loredana ; Roodman, G. David ; Raje, Noopur. / Bone disease in multiple myeloma. Cancer Treatment and Research. Kluwer Academic Publishers, 2016. pp. 251-270 (Cancer Treatment and Research).
@inbook{711ca6533f4649d9a910b9d242192f56,
title = "Bone disease in multiple myeloma",
abstract = "Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90 {\%} of patients with MM develop osteolytic bone lesions, frequently complicated by skeletal-related events (SRE) such as severe bone pain, pathological fractures, vertebral collapse, hypercalcemia, and spinal cord compression. All of these not only result in a negative impact on quality of life but also adversely impact overall survival. OBD is a consequence of increased osteoclast (OC) activation along with osteoblast (OB) inhibition, resulting in altered bone remodeling. OC number and activity are increased in MM via cytokine deregulation within the bone marrow (BM) milieu, whereas negative regulators of OB differentiation suppress bone formation. Inhibition of osteolysis and stimulation of OB differentiation leads to reduced tumor growth in vivo. Therefore, novel agents targeting OBD are promising therapeutic strategies not only for the treatment of MM OBD but also for the treatment of MM. Several novel agents in addition to bisphosphonates are currently under investigation for their positive effect on bone remodeling via OC inhibition or OB stimulation. Future studies will look to combine or sequence all of these agents with the goal of not only alleviating morbidity from MM OBD but also capitalizing on the resultant antitumor activity.",
keywords = "Bone disease, Multiple myeloma, Therapies",
author = "Homare Eda and Loredana Santo and Roodman, {G. David} and Noopur Raje",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-40320-5_14",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "251--270",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",

}

TY - CHAP

T1 - Bone disease in multiple myeloma

AU - Eda, Homare

AU - Santo, Loredana

AU - Roodman, G. David

AU - Raje, Noopur

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90 % of patients with MM develop osteolytic bone lesions, frequently complicated by skeletal-related events (SRE) such as severe bone pain, pathological fractures, vertebral collapse, hypercalcemia, and spinal cord compression. All of these not only result in a negative impact on quality of life but also adversely impact overall survival. OBD is a consequence of increased osteoclast (OC) activation along with osteoblast (OB) inhibition, resulting in altered bone remodeling. OC number and activity are increased in MM via cytokine deregulation within the bone marrow (BM) milieu, whereas negative regulators of OB differentiation suppress bone formation. Inhibition of osteolysis and stimulation of OB differentiation leads to reduced tumor growth in vivo. Therefore, novel agents targeting OBD are promising therapeutic strategies not only for the treatment of MM OBD but also for the treatment of MM. Several novel agents in addition to bisphosphonates are currently under investigation for their positive effect on bone remodeling via OC inhibition or OB stimulation. Future studies will look to combine or sequence all of these agents with the goal of not only alleviating morbidity from MM OBD but also capitalizing on the resultant antitumor activity.

AB - Bone involvement represented by osteolytic bone disease (OBD) or osteopenia is one of the pathognomonic and defining characteristics of multiple myeloma (MM). Nearly 90 % of patients with MM develop osteolytic bone lesions, frequently complicated by skeletal-related events (SRE) such as severe bone pain, pathological fractures, vertebral collapse, hypercalcemia, and spinal cord compression. All of these not only result in a negative impact on quality of life but also adversely impact overall survival. OBD is a consequence of increased osteoclast (OC) activation along with osteoblast (OB) inhibition, resulting in altered bone remodeling. OC number and activity are increased in MM via cytokine deregulation within the bone marrow (BM) milieu, whereas negative regulators of OB differentiation suppress bone formation. Inhibition of osteolysis and stimulation of OB differentiation leads to reduced tumor growth in vivo. Therefore, novel agents targeting OBD are promising therapeutic strategies not only for the treatment of MM OBD but also for the treatment of MM. Several novel agents in addition to bisphosphonates are currently under investigation for their positive effect on bone remodeling via OC inhibition or OB stimulation. Future studies will look to combine or sequence all of these agents with the goal of not only alleviating morbidity from MM OBD but also capitalizing on the resultant antitumor activity.

KW - Bone disease

KW - Multiple myeloma

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=84989893852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989893852&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40320-5_14

DO - 10.1007/978-3-319-40320-5_14

M3 - Chapter

C2 - 27696267

AN - SCOPUS:84989893852

T3 - Cancer Treatment and Research

SP - 251

EP - 270

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -